1. Home
  2. Directory
  3. Kansas
  4. Overland Park
  5. Internal Medicine
  6. NPI Profile
  7. Prescriptions 1235572413

THOMAS ALONZO CUEVAS M.D.
Prescription History 1235572413
Internal Medicine in Overland Park, KS

NPI Status: Active since April 08, 2013

Contact Information

8249 W 95TH ST STE 105
OVERLAND PARK, KS
ZIP 66212
Phone: (913) 652-6640

Get Directions

Prescription History for Informed Healthcare Decisions

Explore the verified Medicare Part D prescription history, volume metrics, and calculated drug costs for THOMAS ALONZO CUEVAS M.D., an active Internal Medicine specialist practicing in Overland Park, KS. Our medical registry currently tracks 5 unique pharmaceutical formulations prescribed by this provider, representing an estimated volume of 114 documented patient claims. Among these therapy options, the most frequently utilized medication is Atovaquone-Proguanil Hcl, which accounts for 36 claims alone.

Medication Index

A
T
Y
No matching medications currently found on file.

Atovaquone-Proguanil Hcl

Generic Formulation: Atovaquone/Proguanil HclSpecialty: Internal Medicine
Provider Metrics Summary
Total Claims 36
30-Day Fills 41.1
Days Supply 935
KS State Average Benchmarks
Peer Average Claims35.0
Peer Average 30-Day Fills38.7
Peer Average Days Supply929
Standard Average Utilization

This provider's prescribing patterns for this therapeutic formulation sit directly in line with standard baseline averages across KS. Gross expenditures recorded under Medicare program tracking definitions for this provider calculate to an estimated aggregate of $4,115.35 across this reporting matrix range.

Provider Avg Cost Per Claim

$114.32

State Avg Cost Per Claim

$148.41

Note on Expenses: These indicators represent gross infrastructure resource tracking paid directly to supply pharmacy networks by Medicare Part D configurations. These calculations do not track individual patient insurance tier copays or out-of-pocket shelf prices at retail checkout lanes.

Therapeutic Applications

This medication contains 2 medicines: atovaquone and proguanil. It is used to prevent and treat malaria caused by mosquito bites in countries where malaria is common. Malaria parasites can enter the body through these mosquito bites, and then live in body tissues such as red blood cells or the liver. This medication is used to kill the malaria parasites living inside red blood cells and other tissues. In some cases, you may need to take a different medication (such as primaquine) to complete your treatment. Both medications may be needed for a complete cure and to prevent the return of infection (relapse). Atovaquone/proguanil belongs to a class of drugs known as antimalarials. The United States Centers for Disease Control provide updated guidelines and travel recommendations for the prevention and treatment of malaria in different parts of the world. Discuss the most recent information with your doctor before traveling to areas where malaria occurs.

Azithromycin

Generic Formulation: AzithromycinSpecialty: Internal Medicine
Provider Metrics Summary
Total Claims 31
30-Day Fills 31.0
Days Supply 120
KS State Average Benchmarks
Peer Average Claims31.0
Peer Average 30-Day Fills33.4
Peer Average Days Supply314
Standard Average Utilization

This provider's prescribing patterns for this therapeutic formulation sit directly in line with standard baseline averages across KS. Gross expenditures recorded under Medicare program tracking definitions for this provider calculate to an estimated aggregate of $115.67 across this reporting matrix range.

Provider Avg Cost Per Claim

$3.73

State Avg Cost Per Claim

$10.54

Note on Expenses: These indicators represent gross infrastructure resource tracking paid directly to supply pharmacy networks by Medicare Part D configurations. These calculations do not track individual patient insurance tier copays or out-of-pocket shelf prices at retail checkout lanes.

Clinical Summary

A semi-synthetic macrolide antibiotic structurally related to ERYTHROMYCIN. It has been used in the treatment of Mycobacterium avium intracellulare infections, toxoplasmosis, and cryptosporidiosis.

Therapeutic Applications

This medication is used to treat certain eye infections. It is a macrolide antibiotic that works by stopping the growth of bacteria. This medication treats only bacterial eye infections. It will not work for other types of eye infections. Unnecessary use or misuse of any antibiotic can lead to its decreased effectiveness.

Twinrix

Generic Formulation: Hepatitis A And B Vaccine/PfSpecialty: Internal Medicine
Provider Metrics Summary
Total Claims 11
30-Day Fills 11.0
Days Supply 11
KS State Average Benchmarks
Peer Average Claims186.0
Peer Average 30-Day Fills186.0
Peer Average Days Supply186
Highly Conservative Utilization

This provider demonstrates a highly selective approach to this formula, recording 94.1% less volume than the regional standard for practitioners inside KS. Gross expenditures recorded under Medicare program tracking definitions for this provider calculate to an estimated aggregate of $1,965.07 across this reporting matrix range.

Provider Avg Cost Per Claim

$178.64

State Avg Cost Per Claim

$141.34

Note on Expenses: These indicators represent gross infrastructure resource tracking paid directly to supply pharmacy networks by Medicare Part D configurations. These calculations do not track individual patient insurance tier copays or out-of-pocket shelf prices at retail checkout lanes.

Typhim Vi

Generic Formulation: Typhoid Vi Polysacch VaccineSpecialty: Internal Medicine
Provider Metrics Summary
Total Claims 25
30-Day Fills 25.0
Days Supply 54
KS State Average Benchmarks
Peer Average Claims20.0
Peer Average 30-Day Fills20.5
Peer Average Days Supply64
Standard Average Utilization

This provider's prescribing patterns for this therapeutic formulation sit directly in line with standard baseline averages across KS. Gross expenditures recorded under Medicare program tracking definitions for this provider calculate to an estimated aggregate of $2,755.64 across this reporting matrix range.

Provider Avg Cost Per Claim

$110.23

State Avg Cost Per Claim

$133.93

Note on Expenses: These indicators represent gross infrastructure resource tracking paid directly to supply pharmacy networks by Medicare Part D configurations. These calculations do not track individual patient insurance tier copays or out-of-pocket shelf prices at retail checkout lanes.

Yf-Vax

Generic Formulation: Yellow Fever Vaccine Live/PfSpecialty: Internal Medicine
Provider Metrics Summary
Total Claims 11
30-Day Fills 11.0
Days Supply 11
KS State Average Benchmarks
Peer Average Claims13.0
Peer Average 30-Day Fills13.0
Peer Average Days Supply13
Standard Average Utilization

This provider's prescribing patterns for this therapeutic formulation sit directly in line with standard baseline averages across KS. Gross expenditures recorded under Medicare program tracking definitions for this provider calculate to an estimated aggregate of $1,534.22 across this reporting matrix range.

Provider Avg Cost Per Claim

$139.47

State Avg Cost Per Claim

$199.81

Note on Expenses: These indicators represent gross infrastructure resource tracking paid directly to supply pharmacy networks by Medicare Part D configurations. These calculations do not track individual patient insurance tier copays or out-of-pocket shelf prices at retail checkout lanes.

Dataset Methodology & CMS Source Information

This analytical profile maps public infrastructure records sourced directly from official **Centers for Medicare & Medicaid Services (CMS)** public data releases. The statistics above track documented pharmaceutical treatment trends assigned to beneficiaries specifically under federal public programs. Evaluating the prescriptive footprints of clinical practitioners like THOMAS ALONZO CUEVAS M.D. provides transparency into local medical care patterns within Overland Park, KS.

Key Learning Objectives for this Profile:

  • Prescribing Frequencies: Track and evaluate the volume metrics of specific brand-name and generic medical formulas chosen by this provider over time.
  • Clinical Focus Areas: Identify how the provider distributes therapeutic selections across medical care options to gain insight into their true day-to-day **Internal Medicine** practice concentrations.
  • Program Cost Awareness: Review the calculated total systemic drug costs and raw transactional volumes linked to these orders to better anticipate network insurance coverage structures.
  • Patient-Centered Evaluation: Cross-reference localized regional care comparisons to align practitioner habits directly with your proactive health maintenance goals.

Data Scope Exclusion & Limitations: The data elements presented above explicitly reflect prescription orders processed for Medicare beneficiaries during the year 2023. This informational profile does not aggregate prescription data for individuals utilizing private commercial health plans, state Medicaid coverage, or self-pay options. However, because medical decision-making remains highly consistent across clinical settings, this public registry provides a reliable proxy for understanding the general prescribing preferences and pharmaceutical care approach used by this provider.